-+ 0.00%
-+ 0.00%
-+ 0.00%

Castle Biosciences' DecisionDx-Melanoma Predicts Five-Year Recurrence More Accurately Than AJCC Staging in Study

PUBT·11/11/2026 12:03:17
Listen to the news
Castle Biosciences' DecisionDx-Melanoma Predicts Five-Year Recurrence More Accurately Than AJCC Staging in Study
  • Castle Biosciences will present DecisionDx-Melanoma study results at SDPA Nov. 11-15, 2026, and Dermato-Onco2026 Nov. 12-13.
  • A study of 750 patients found the test identified higher mortality risk in some thin melanomas traditionally considered low risk.
  • Another study of 1,726 patients found its recurrence-risk algorithm predicted five-year recurrence more accurately than standard melanoma staging.
  • The findings support individualized risk assessment to help clinicians tailor patient follow-up and surveillance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611110700PR_NEWS_USPR_____DA94676) on November 11, 2026, and is solely responsible for the information contained therein.